+162.8%
FTNT vs MRNA
-67.9%
+230.7%
-38.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.8% | +5.4% | -7.1% | -2.0% |
| 7D | -0.1% | -1.1% | +0.9% | -0.1% |
| 30D | -3.0% | +126.1% | -129.1% | -11.0% |
| 3M | +7.6% | +190.0% | -182.4% | -5.7% |
| 6M | +87.0% | +157.2% | -70.3% | +66.1% |
| YTD | +96.5% | +388.2% | -291.7% | +55.6% |
| 1Y | +92.9% | +467.0% | -374.1% | +47.4% |
| 3Y | +139.8% | +36.1% | +103.8% | +121.6% |
| All | +162.8% | -67.9% | +230.7% | +189.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling